Adipotide
Also known as: CKGGRAKDC-GG-(D)(KLAKLAK)2, Proapoptotic peptidomimetic targeting white adipose tissue, ATS-KLAKLAK, Fat-targeted peptidomimetic
Ligand-directed peptidomimetic / pro-apoptotic peptide conjugate
What it is
Adipotide is a compound studied in animals for reducing body fat by cutting off the blood supply to fat tissue, causing it to break down. Early research showed significant weight loss in obese monkeys, but it also caused kidney toxicity. No FDA-approved use; research remains at a preclinical stage.
The scientific side
Adipotide is a peptidomimetic composed of a white adipose tissue (WAT) vascular-targeting sequence (CKGGRAKDC) linked to a pro-apoptotic peptide domain [(D)(KLAKLAK)2]. It is designed to home to prohibitin (PHB1)-expressing endothelial cells on the vasculature of white adipose tissue and induce targeted apoptosis within those blood vessels, leading to reduction of WAT and weight loss. In obese non-human primates, treatment resulted in rapid weight loss, reduced white adipose tissue mass confirmed by MRI and DEXA, and improved insulin resistance. In obese mice, a pro-apoptotic peptide with the same mechanism improved glucose tolerance rapidly and in a weight- and food intake-independent manner, and altered lipid metabolism and mitochondrial pathways in adipose tissue. A nanoparticle-targeted formulation using the same PHB-targeting approach (KLA-PTNP) similarly reduced body weight and improved adipose tissue function in diet-induced obese mice. The adipose targeting sequence (ATS) has also been studied as a targeting vehicle for liposomal drug delivery to adipose endothelium. PHB1 on the adipose vascular endothelium also mediates bidirectional long-chain fatty acid transport, and ANX2/PHB interaction regulates fatty acid transport in WAT, providing additional biological context for PHB as an adipose vascular target.
Class: Ligand-directed peptidomimetic / pro-apoptotic peptide conjugate
Administration & storage
- Administration
- Systemic injection (PMID: 23871959)Route not specified in other abstracts (PMID: 22072637PMID: 22733798)
- Storage
- No storage conditions are described in the reviewed abstracts.
- Cautions
- Predictable and reversible changes in renal proximal tubule function were observed in monkeys from three species at experimentally determined optimal doses.,Dose-limiting renal toxicity (nephrotoxicity with proteinuria, casts, and increased serum creatinine) has been observed with a related peptidomimetic (BMTP-11) from the same D(KLAKLAK)2-containing class of agents in a human first-in-man trial.,ATS-targeted liposomes showed increased kidney uptake in biodistribution studies in ob/ob mice, raising potential off-target renal concerns.,One published comment suggests that the weight loss observed in obese monkeys may partly reflect a direct effect on food consumption rather than solely WAT apoptosis.,No human clinical trial data for Adipotide itself are available in the reviewed literature; all dosing and safety data are from animal studies only.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Weight loss and reduction of white adipose tissue in obesity Animal studies only
- Treatment of obese Old World monkeys with adipotide (CKGGRAKDC-GG-(D)(KLAKLAK)2) induced targeted apoptosis in blood vessels of WAT, rapid weight loss, and reduced WAT confirmed by MRI and DEXA, across three primate species. PMID 22072637 Barnhart et al., Science Translational Medicine (2011)
- A pro-apoptotic peptide targeting WAT endothelium in obese mice on high-fat diet rapidly and potently improved glucose tolerance in a weight- and food intake-independent manner; serum insulin and triglycerides were decreased. PMID 22733798 Kim et al., Diabetes (2012)
- Systemic injection of diet-induced obese mice with a prohibitin-targeted nanoparticle (KLA-PTNP) reduced body weight (evidenced by decreased serum leptin), improved dysfunctional adipose tissue, and reduced ectopic fat in liver and muscle; compared to Adipotide bioconjugate. PMID 23871959 Hossen et al., Journal of Controlled Release (2013)
- Improvement of insulin resistance / glucose tolerance in obesity Animal studies only
- Adipotide treatment resulted in improved insulin resistance in obese non-human primates. PMID 22072637 Barnhart et al., Science Translational Medicine (2011)
- Pro-apoptotic peptide targeting WAT endothelium rapidly improved glucose tolerance of obese mice; effect was independent of weight loss or food intake reduction. PMID 22733798 Kim et al., Diabetes (2012)
- Depletion of white adipocyte progenitors to suppress obesity Animal studies only
- A hunter-killer peptide designed to induce apoptosis selectively in white adipocyte progenitors (WAP) caused long-term WAT growth suppression despite increased caloric intake in a mouse diet-induced obesity model; WAP depletion led to compensatory beige adipocyte population and increased energy expenditure. PMID 25342467 Daquinag et al., Cell Death and Differentiation (2015)
- Targeting prohibitin-expressing adipose vasculature for drug delivery Animal studies only
- PHB and ANX2 interact on the surface of WAT vascular endothelial cells and adipocytes to regulate CD36-mediated fatty acid transport; this pathway is a potential target for metabolic disease intervention. PMID 27468426 Salameh et al., JCI Insight (2016)
- ATS-conjugated liposomes were evaluated for biodistribution in ob/ob mice; ATS targeting did not increase liposomal uptake in adipose tissue relative to other tissues but did increase kidney uptake; ATS targeting did not significantly alter metabolic parameters. PMID 31725756 Bauknight et al., PLoS ONE (2019)
Safety signals
- Predictable and reversible changes in renal proximal tubule function observed in obese non-human primates (three species) treated at experimentally determined optimal doses PMID 22072637
- A published comment raises the possibility that weight loss in adipotide-treated monkeys may partly reflect reduced food consumption (direct effect on feeding behavior) rather than solely WAT apoptosis, introducing uncertainty about the primary mechanism PMID 22539771
- ATS-targeted liposomes showed unexpectedly increased kidney uptake in biodistribution studies in ob/ob mice, suggesting potential off-target renal accumulation with peptide-targeted adipose delivery systems PMID 31725756
- Related D(KLAKLAK)2-class peptidomimetic (BMTP-11) caused dose-dependent, reversible nephrotoxicity with proteinuria and casts and increased serum creatinine as a dose-limiting toxicity in a first-in-man clinical trial PMID 25832466
Contraindications
- No explicit contraindications for Adipotide are stated in the reviewed abstracts. Pre-existing renal impairment may be a concern given observed renal proximal tubule effects in non-human primates and nephrotoxicity with a related agent in humans — but this is not explicitly stated as a contraindication in any abstract. PMID 22072637
Protocol
No community dose for Adipotide on record yet.
All studies (9)
- PMID 22072637 Animal studies only
Weight loss and reduction of white adipose tissue in obesity - PMID 22539771
A published comment raises the possibility that weight loss in adipotide-treated monkeys may partly reflect reduced food consumption (direct effect on feeding b - PMID 22733798 Animal studies only
Weight loss and reduction of white adipose tissue in obesity - PMID 23871959 Animal studies only
Weight loss and reduction of white adipose tissue in obesity - PMID 25342467 Animal studies only
Depletion of white adipocyte progenitors to suppress obesity - PMID 25832466
Related D(KLAKLAK)2-class peptidomimetic (BMTP-11) caused dose-dependent, reversible nephrotoxicity with proteinuria and casts and increased serum creatinine as - PMID 27468426 Animal studies only
Targeting prohibitin-expressing adipose vasculature for drug delivery - PMID 31725756 Animal studies only
Targeting prohibitin-expressing adipose vasculature for drug delivery - PMID 35499627
Frequently asked
What is adipotide and how does it cause weight loss?
Adipotide is a peptidomimetic (CKGGRAKDC-GG-(D)(KLAKLAK)2) designed to home to prohibitin-expressing endothelial cells in white adipose tissue (WAT) vasculature and induce targeted apoptosis in those blood vessels, leading to WAT reduction and weight loss. In obese non-human primates, treatment resulted in rapid weight loss, reduced WAT confirmed by MRI and DEXA, and improved insulin resistance. A pro-apoptotic peptide with the same mechanism also rapidly improved glucose tolerance in obese mice independently of weight loss.
Has adipotide been tested in humans?
Based on the reviewed literature, no human clinical trial data for Adipotide itself are available. All efficacy and safety data come from animal studies — primarily obese non-human primates and obese mice (PMID 22733798, PMID 23871959). A closely related D(KLAKLAK)2-class drug (BMTP-11 targeting IL-11Rα) has entered first-in-man trials in cancer patients, but this is a distinct compound.
What dose of adipotide should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: Exact doses used in non-human primate studies are described only as 'experimentally determined optimal doses' in the available abstracts. No human dosing data exist in the reviewed literature. Please consult a licensed healthcare provider.
Is adipotide safe? What are the side effects?
Based on the reviewed abstracts, predictable and reversible changes in renal proximal tubule function were observed in obese non-human primates treated with adipotide. A related drug from the same class (BMTP-11) caused dose-dependent, reversible nephrotoxicity with proteinuria and increased serum creatinine in a human trial. One published comment also questions whether some weight loss in monkeys reflects reduced food intake rather than WAT apoptosis alone. There are no human safety data for Adipotide itself in the reviewed literature.
Can I stack adipotide with other peptides or weight loss compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Adipotide has been studied as a monotherapy in animal models (PMID 22072637, PMID 22733798). No combination studies with other peptides or compounds are reported in the reviewed literature.
Where can I buy adipotide?
I don't recommend vendors or sources. Please consult a licensed provider.
Does adipotide improve insulin resistance or blood sugar?
In obese non-human primates, adipotide treatment resulted in improved insulin resistance. In obese mice on a high-fat diet, a pro-apoptotic peptide with the same mechanism rapidly and potently improved glucose tolerance in a weight- and food intake-independent manner, and decreased serum insulin and triglycerides. These are animal data only; no human data are available in the reviewed literature.
What is the difference between adipotide and the prohibitin-targeted nanoparticle (KLA-PTNP)?
Both Adipotide (a bioconjugate) and KLA-PTNP (a nanoparticle formulation) use a prohibitin-targeting peptide to direct a pro-apoptotic payload to white adipose tissue vasculature. A comparative study in diet-induced obese mice found that the low-dose nanoparticle formulation (KLA-PTNP) reduced body weight and improved dysfunctional adipose tissue and ectopic fat deposition, with effects attributed in part to multivalent active targeting and enhanced endosomal escape. Direct comparison of the two formats' efficacy and safety profiles in humans has not been studied.
Can adipotide treat obesity-related diabetes or metabolic syndrome?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. In animal research, a pro-apoptotic peptide targeting WAT endothelium improved glucose tolerance rapidly and independently of weight loss in obese mice, and reduced ectopic fat in liver and muscle in diet-induced obese mice. These are preclinical findings only.
What is the regulatory status of adipotide?
The reviewed scientific literature does not explicitly state the current regulatory status of adipotide with the US FDA, Health Canada, or WADA. This requires manual verification with the relevant regulatory bodies. No IND or clinical trial approval for Adipotide itself is mentioned in the reviewed abstracts.